The Absolute Best Science Experiment for 3731-52-0

If you are hungry for even more, make sure to check my other article about 3731-52-0, Name: Pyridin-3-ylmethanamine.

Let¡¯s face it, organic chemistry can seem difficult to learn, Name: Pyridin-3-ylmethanamine, Especially from a beginner¡¯s point of view. Like 3731-52-0, Name is Pyridin-3-ylmethanamine, molecular formula is C5H4O3, belongs to furans-derivatives compound. In a document, author is Jansen, Bernard H. E., introducing its new discovery.

Simplified Methods for Quantification of F-18-DCFPyL Uptake in Patients with Prostate Cancer

Radiolabeled prostate-specific membrane antigen (PSMA) PET has demonstrated promising results for prostate cancer (PCa) imaging. Quantification of PSMA radiotracer uptake is desired as it enables reliable interpretation of PET images, use of PSMA uptake as an imaging biomarker for tumor characterization, and evaluation of treatment effects. The aim of this study was to perform a full pharmacokinetic analysis of 2-(3-(1-carboxy-5-[(6-F-18-fluoro-pyridine-3-carbonyl)amino]-pentyl)-ureido)-pentanedioic acid (F-18-DCFPyL), a secondgeneration F-18-labeled PSMA ligand. On the basis of the pharmacokinetic analysis (reference method), simplified methods for quantification of F-18-DCFPyL uptake were validated. Methods: Eight patients with metastasized PCa were included. Dynamic PET acquisitions were performed at 0-60 and 90-120 min after injection of a median dose of 313 MBq of F-18-DCFPyL (range, 292-314 MBq). Continuous and manual arterial blood sampling provided calibrated plasma tracer input functions. Time-activity curves were derived for each PCa metastasis, and F-18-DCFPyL kinetics were described using standard plasma input tissue-compartment models. Simplified methods for quantification of F-18-DCFPyL uptake (SUVs; tumor-to-blood ratios [TBRs]) were correlated with kinetic parameter estimates obtained from full pharmacokinetic analysis. Results: In total, 46 metastases were evaluated. A reversible 2-tissue-compartment model was preferred for 18F-DCFPyL kinetics in 59% of the metastases. The observed k(4) was small, however, resulting in nearly irreversible kinetics during the course of the PET study. Hence, k(4) was fixated (0.015) and net influx rate, Ki, was preferred as the reference kinetic parameter. Whole-blood TBR provided an excellent correlation with Ki from full kinetic analysis (R-2 = 0.97). This TBR could be simplified further by replacing the blood samples with an image-based, single measurement of blood activity in the ascending aorta (image-based TBR, R-2 = 0.96). SUV correlated poorly with Ki (R-2 = 0.47 and R-2 = 0.60 for SUV normalized to body weight and lean body mass, respectively), most likely because of deviant blood activity concentrations (i.e., tumor tracer input) in patients with higher tumor volumes. Conclusion: F-18-DCFPyL kinetics in PCa metastases are best described by a reversible 2-tissuecompartment model. Image-based TBRs were validated as a simplified method to quantify F-18-DCFPyL uptake andmight be applied to clinical, whole-body PET scans. SUV does not provide reliable quantification of F-18-DCFPyL uptake.

If you are hungry for even more, make sure to check my other article about 3731-52-0, Name: Pyridin-3-ylmethanamine.

Reference:
Pyridine – Wikipedia,
,Pyridine | C5H5N – PubChem